SPRO (Spero Therapeutics, Inc. Common Stock) Stock Analysis - News
Spero Therapeutics, Inc. Common Stock (SPRO) is a publicly traded Healthcare sector company. As of May 21, 2026, SPRO trades at $2.64 with a market cap of $149.39M and a P/E ratio of 0.00. SPRO moved +1.16% today. Year to date, SPRO is +8.23%; over the trailing twelve months it is +286.65%. Its 52-week range spans $0.51 to $3.22. Rallies surfaces SPRO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in SPRO news today?
Spero Therapeutics’ Q1 Loss Narrows to $7.2M as PDUFA Date Set June 18: Spero reported a Q1 net loss of $7.2 million, down from $13.9 million a year earlier, on $0.3 million revenue while R&D expenses fell to $2.9 million. Its NDA for oral carbapenem tebipenem HBr is under FDA review with a June 18 PDUFA date, and its cash runway extends into 2028.
Rajavelu Esther sold 25.24K (~$63.35K) on May 4, 2026.
Rajavelu Esther sold 37.10K (~$87.56K) on Feb 6, 2026.
Rajavelu Esther sold 50.82K (~$119.93K) on Feb 6, 2026.
SPRO Analyst Consensus
SPRO analyst coverage data. Average price target: $0.00.
Common questions about SPRO
What changed in SPRO news today?
Spero Therapeutics’ Q1 Loss Narrows to $7.2M as PDUFA Date Set June 18: Spero reported a Q1 net loss of $7.2 million, down from $13.9 million a year earlier, on $0.3 million revenue while R&D expenses fell to $2.9 million. Its NDA for oral carbapenem tebipenem HBr is under FDA review with a June 18 PDUFA date, and its cash runway extends into 2028.
Does Rallies summarize SPRO news?
Yes. Rallies summarizes SPRO news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is SPRO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for SPRO. It does not provide personalized investment advice.
